Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Tiny study on clotting disorder and artery health ends early

NCT ID NCT01160159

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to see if women with thrombophilia (a condition that makes blood clot more easily) have differences in artery function compared to healthy women. Researchers planned to measure blood vessel dilation and other artery health markers. However, the study was terminated early after enrolling only 6 participants, so no meaningful conclusions could be drawn.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

6 people

The number who actually took part.

Started

Mar 2010

Finished

Apr 2010

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Two groups of 80 women will be compared: healthy volunteers and women with thrombophilia.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * healthy volunteers * 18-45 years old women of child bearing age * Without any hormonal contraception nor any hormone treatment since at least 3 months * Without any arterial risk factors (HTA, diabetes, dyslipemia, obesity, including smoking\> 5 cigaret ) * Patient who have signed an inform consent * With no thrombophilia : normal sample for factor V and II mutations * Willing to participate to the study * Adherent to health insurance * Previous Clinical examination * women with thrombophilia * 18-45 years old women of child bearing age * Without any hormonal contraception nor any hormone treatment since at least 3 months * Without any arterial risk factors (HTA, diabetes, dyslipemia, obesity, including smoking\> 5 cigaret ) * Patient who have signed an inform consent * With thrombophilia : normal sample for factor V and II mutations * Willing to participate to the study * Adherent to health insurance * Previous Clinical examination Exclusion Criteria: * Women under hormonal contraception or who have stopped it less than 3 months ago * Women under anticoagulant * Arterial risk factor : HTA, diabetes, dyslipemia, obesity(BMI\>30), including smoking\> 5 cigarets ), metabolic syndrome, antiphospholipids/anticoagulant antibody, SLE * History of coronaropathy or of stroke * Pregnant women or willing to conceive * Severe liver disease * Women of less than 18y or older than 45y * Severe liver diseases * Patient not willing to sign up the inform consent * Patient refusal to participate * Endometrial cancer * Unexplored bleeding * Women not willing to participate or included in another trial * Woman with another thrombophilic disorder (ATIII, protein C, S, history of VTE without any biological thrombophilic disorder. * Women with at least one of the following treatment and who cannot stop it 48h before the arterial investigations. * Gynergen caffeine * NOCERTONE® oxetorone * SIBÉLIUM®flunarizine * VIDORA®indoramine * SANMIGRAN® 0,50 mg pizotifen * woman under propranolol AVLOCARDYL® 40 mg \*AVLOCARDYL® LP 160 mg

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thrombophilia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

thrombophilia Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Hotel Dieu - Consultation Gynécologie et d'Hémostase

    Paris, 75004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.